Idarucizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Idarucizumab: From Dabigatran Reversal to Hemoglobinopathy
One-Sentence Summary
Idarucizumab is a humanized antibody fragment (Fab) that binds dabigatran and neutralizes its anticoagulant effect. It is marketed in Singapore as Praxbind. The TxGNN model predicts it may be effective for hemoglobinopathy, but no clinical trials and no publications support this prediction. The high score appears to be a graph-based artifact rather than a biologically grounded signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore license record (the drug is known to reverse the anticoagulant effect of dabigatran) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 95.66% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, idarucizumab binds dabigatran with high affinity and neutralizes its anticoagulant activity. It is a targeted reversal agent, not a disease-modifying drug.
This mechanism has no plausible connection to hemoglobin disorders, which involve abnormal globin chains or red cell function. The high TxGNN score most likely reflects network proximity in the knowledge graph rather than real biological support. The same applies to the other top-ranked predictions (rheumatoid arthritis, beta-thalassemia, pyruvate kinase deficiency, hereditary pyropoikilocytosis, bronchitis, gout and others). None has a supporting mechanism, trial or publication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for hemoglobinopathy.
For reference, the only publication retrieved across the top 10 predictions was linked to gout (rank 9). It does not support repurposing:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31381100 | 2019 | Case report | Am J Health Syst Pharm | Dabigatran-associated coagulopathy lasting about 1 week despite several treatments (hemodialysis, fresh frozen plasma, two idarucizumab doses) in a patient with acute kidney injury. It concerns the approved use, not gout. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15083P | PRAXBIND SOLUTION FOR INJECTION/INFUSION 50 MG/ML | Injection, solution | Not stated in the license record |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. There are no trials, no relevant literature and no plausible mechanism linking dabigatran reversal to hemoglobinopathy. The evidence level is L5.
To proceed, the following is needed:
- Retrieve the package insert from the HSA website to confirm approved indications, warnings and contraindications
- Obtain mechanism of action data from DrugBank
- A credible biological rationale for hemoglobinopathy, followed by preclinical evidence, before any clinical consideration
- Confirmation of route compatibility (currently pending; the drug is available only as an injectable)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.